-
EP3647323
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3647323
| EP3647323 - ANTI-GITR ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 02.09.2022 Database last updated on 24.08.2024 | |
| Former | Request for examination was made Status updated on 03.04.2020 | ||
| Former | The international publication has been made Status updated on 04.01.2019 | Most recent event Tooltip | 02.09.2022 | Application deemed to be withdrawn | published on 05.10.2022 [2022/40] | Applicant(s) | For all designated states Jiangsu Hengrui Medicine Co., Ltd. No. 7 Kunlunshan Road Economic and Technological Development Zone Lianyungang Jiangsu 222047 / CN | For all designated states Shanghai Hengrui Pharmaceutical Co., Ltd No.279 Wenjing Road Economic and Technological Development Zone Minhang District Shanghai 200245 / CN | [2020/19] | Inventor(s) | 01 /
YAN, Shude No.7 Kunlunshan Road Economic and Technological Development Zone Lianyungang Jiangsu 222047 / CN | 02 /
JIANG, Jiahua No.7 Kunlunshan Road Economic and Technological Development Zone Lianyungang Jiangsu 222047 / CN | 03 /
HUANG, Hao No.7 Kunlunshan Road Economic and Technological Development Zone Lianyungang Jiangsu 222047 / CN | 04 /
ZHANG, Lianshan No.7 Kunlunshan Road Economic and Technological Development Zone Lianyungang Jiangsu 222047 / CN | 05 /
CAO, Guoqing No.7 Kunlunshan Road Economic and Technological Development Zone Lianyungang Jiangsu 222047 / CN | [2020/19] | Representative(s) | dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE | [2020/19] | Application number, filing date | 18824945.2 | 29.06.2018 | [2020/19] | WO2018CN93572 | Priority number, date | CN201710522742 | 30.06.2017 Original published format: CN201710522742 | [2020/19] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019001559 | Date: | 03.01.2019 | Language: | ZH | [2019/01] | Type: | A1 Application with search report | No.: | EP3647323 | Date: | 06.05.2020 | Language: | EN | [2020/19] | Search report(s) | International search report - published on: | CN | 03.01.2019 | (Supplementary) European search report - dispatched on: | EP | 28.09.2021 | Classification | IPC: | C07K16/28, C07K16/46, C12N15/13, A61K39/395, A61P35/00 | [2020/19] | CPC: |
C07K16/2878 (EP);
C07K16/28 (US);
A61K47/68 (US);
A61P35/00 (EP,US);
C07K16/46 (US);
A61K2039/505 (EP);
C07K2317/24 (EP);
C07K2317/73 (EP);
C07K2317/76 (EP);
C07K2317/92 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/19] | Title | German: | ANTI-GITR-ANTIKÖRPER, ANTIGENBINDENDES FRAGMENT DAVON UND PHARMAZEUTISCHE VERWENDUNG DAVON | [2020/19] | English: | ANTI-GITR ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF | [2020/19] | French: | ANTICORPS ANTI-GITR, FRAGMENT DE LIAISON À L'ANTIGÈNE DE CELUI-CI ET UTILISATION PHARMACEUTIQUE ASSOCIÉE | [2020/19] | Entry into regional phase | 20.01.2020 | Translation filed | 20.01.2020 | National basic fee paid | 20.01.2020 | Search fee paid | 20.01.2020 | Designation fee(s) paid | 20.01.2020 | Examination fee paid | Examination procedure | 20.01.2020 | Examination requested [2020/19] | 15.06.2020 | Amendment by applicant (claims and/or description) | 28.04.2022 | Application deemed to be withdrawn, date of legal effect [2022/40] | 19.05.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/40] | Fees paid | Renewal fee | 20.01.2020 | Renewal fee patent year 03 | 28.06.2021 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 30.06.2022 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2011028683 (SCHERING CORP [US], et al) [I] 1-8,10-17 * Examples 2, 4, 5 (Treatment of Tumors with TGF-beta and GITR Antibodies) *; | [I]WO2013039954 (SANOFI SA [FR], et al) [I] 1-8,10-17 * examples 1-4,6-10 *; | [ID]WO2015184099 (4ANTIBODY AG [CH], et al) [ID] 1-8,10-17 * examples 1,2,7 *; | [I]WO2015187835 (SQUIBB BRISTOL MYERS CO [US]) [I] 1-8,10-17 * examples 1-4; claim 1 *; | [ID]WO2016054638 (DANA FARBER CANCER INST INC [US]) [ID] 1-8,10-17 * paragraphs [0025] , [0026] , [0090] , [0091] , [0131] - [0134]; figures 2,3; claims 19,20 *; | [A] - GIUSEPPE NOCENTINI ET AL, "Pharmacological modulation of GITRL/GITR system: therapeutic perspectives", BRITISH JOURNAL OF PHARMACOLOGY, (20120309), vol. 165, no. 7, doi:10.1111/j.1476-5381.2011.01753.x, ISSN 0007-1188, pages 2089 - 2099, XP055150987 [A] 1-8,10-17 DOI: http://dx.doi.org/10.1111/j.1476-5381.2011.01753.x | International search | [XA]US2013108641 (BAURIN NICOLAS [FR], et al) [X] 15-22, 24-25 * claims 1-28claims 1-28 *[A] 1-14, 23; | [XA]CN105829343 (AMGEN INC) [X] 15-22, 24-25 * claims 1-44claims 1-44 * [A] 1-14, 23; | [XA]CN106459203 (SQUIBB BRISTOL MYERS CO) [X] 15-22, 24-25 * claims 1-60claims 1-60 * [A] 1-14, 23 | by applicant | WO2006105021 | WO2011028683 | WO2013039954 | WO2015031667 | WO2015184099 | WO2015187835 | WO2016054638 | WO2017068186 | WO2017087678 | - J. Biol. Chem, (19680000), vol. 243, page 3558 |